EP0055070A1 - Antibiotic A-4696 factors B1,B2,B3,C1a,C3 and E1 - Google Patents

Antibiotic A-4696 factors B1,B2,B3,C1a,C3 and E1 Download PDF

Info

Publication number
EP0055070A1
EP0055070A1 EP81305898A EP81305898A EP0055070A1 EP 0055070 A1 EP0055070 A1 EP 0055070A1 EP 81305898 A EP81305898 A EP 81305898A EP 81305898 A EP81305898 A EP 81305898A EP 0055070 A1 EP0055070 A1 EP 0055070A1
Authority
EP
European Patent Office
Prior art keywords
percent
antibiotic
atcc
factor
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP81305898A
Other languages
German (de)
French (fr)
Other versions
EP0055070B1 (en
Inventor
Manuel Debono
Kurt Edgar Merkel
Robert Edgar Weeks
Herald James Cole
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to AT81305898T priority Critical patent/ATE23192T1/en
Publication of EP0055070A1 publication Critical patent/EP0055070A1/en
Application granted granted Critical
Publication of EP0055070B1 publication Critical patent/EP0055070B1/en
Expired legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/06Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using actinomycetales
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/045Actinoplanes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/19Antibiotic
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/27Cyclic peptide or cyclic protein

Definitions

  • This invention concerns novel factors B 1 , B 2 , B 3' C 1a , C 3 and E 1 of actaplanin antibiotic A-4696. They are effective antibacterial and antimicrobial agents as well as growth promotant agents in poultry, swine, sheep and beef cattle.
  • the present invention is related generally to the inventions disclosed in U.S. Patent 3,952,095 issued April 20, 1976, for novel antibiotic and a process for the production thereof, U.S. Patent No. 4,064,233 issued December 20, 1977, for antibiotic A-4696, and U.S. Patent 4,115,552 issued September 19, 1978, for factor A and B of antibiotic A-4696.
  • Factor B of antibiotic A-4696 described in U.S. Patent 4,064,233 and U.S. Patent 4,115,552, is not the same as any of the factors claimed in the present application. Furthermore, none of the present antibiotic A-4696 factors were known, appreciated, or even suspected prior to the present invention.
  • the antibiotic A-4696 factors B 1 , B 2' B 3 , C 1a , C 3 and E 1 are isolated from the A-4696 complex which is produced by culturing a microorganism Actinoplanes missouriensis ATCC 31680, ATCC 31682 or ATCC 31683 in a culture medium containing assimilable sources of carbohydrate, nitrogen and inorganic salts under submerged aerobic fermentation conditions until a substantial amount of antibiotic activity is produced.
  • the method for increasing the feed utilization efficiency in ruminant animals is accomplished by administering to the ruminant animals a growth promotant amount of the antibiotic A-4696 complex or the A-4696 factors B 1 , B 2 , B 3' C la' C 3 and/or E 1 or a pharmaceutically acceptable acid addition salt thereof in the form of a feed, feed premix or feed supplement.
  • the method for promoting the growth of chickens comprises administering to the chickens either in their diet or drinking water a growth promotant amount of the antibiotic A-4696 complex or the novel factors B 1 , B 2 , B 3' C 1a , C 3 and/or E 1 , or a pharmaceutically acceptable salt thereof.
  • the present invention relates to novel factors B 1 , B 2 , B 3 , C 1a , C 3 , and E l , of actaplanin antibiotic A-4696.
  • novel factors of antibiotic A-4696 are isolated from antibiotic A-4696, the latter being produced by culturing a microorganism belonging to the genus Actinoplanes in a nutrient medium until substantial antibacterial activity is detected in the culture medium.
  • the antibiotic A-4696 complex as disclosed in related applications listed herein above, comprises several heretofore unknown factors designated as B 1 , B 2 r B 3' C 1a , and C 3 .
  • An additional factor, designated as E 1 can also be isolated from the antibiotic A-4696 complex and may represent a degradation product.
  • the chemical, physical, and biological properties of the factors indicate that they are new antibiotics and, except possibly for factor E 1 , that they are composed of the same peptide core (aglycone) and amino sugar, and varying amounts of glucose, mannose, and rhamnose. While factor E 1 is similar in most respects to the other factors, it is possible that it possesses a somewhat modified peptide core.
  • Bioautography of aglycone formation during hydrolysis of both the A-4696 complex and the individual factors shows that within a short time a simple mixture of antimicrobially active pseudo-aglycone and aglycone is obtained. It is possible that the site of antimicrobial activity of the A-4696 complex and individual factors resides in the peptide pseudo-aglycone, with the factors being substantially differentiated by differences in their neutral sugar composition. The attached sugars may function chiefly to modulate solubility and other important pharmaco- dynamic parameters. However, the manner in which the antibiotic factors claimed herein function or are produced does not constitute a part of the invention, and applicant does not intend to be limited in any way by the postulated mode of action stated herein.
  • the antibiotic factors of this invention are isolated from antibiotic A-4696 which is produced by culturing the organism Actinoplanes missouriensis in an aqueous nutrient medium under submerged aerobic fermentation conditions.
  • the antibiotic A-4696 complex is first separated from the fermentation broth and then the individual factors are isolated by liquid chromatography.
  • the antibiotic factors of the present invention are converted to a hydrochloride or sulfate salt.
  • the term 'antibiotic A-4696' is used to designate the actaplanin antibiotic complex, while the various factors isolated from the complex are designated as antibiotic A-4696 factors A, B 1 , B 2' B 3' C 1a , C 3' E 1 , and so forth.
  • Antibiotic A-4696 and the individual factors isolated therefrom are highly effective in preventing the growth of microorganisms which are pathogenic to both man and animals.
  • the antibiotic factors of the present invention have agricultural application as growth promotants in chickens, swine, sheep, and beef cattle.
  • novel antibiotic factors B 1 , B 2, B 3' C 1a , C3, and E 1 of antibiotic A-4696 are basic compounds capable of forming salts with suitable acids and are isolated from antibiotic A-4696 which is produced by culturing a microorganism belonging to the species Actinoplanes missouriensis in a nutrient medium until substantial antibacterial activity is detected in the culture medium.
  • the characterization data presented below are for the antibiotic A-4696 factors in the form of their hydrochloride salts, although other pharmaceutically acceptable salts can also be prepared by employing methods known in the art.
  • Antibiotic A-4696 factor A was previously isolated and is substantially as disclosed in U.S. Patent 4,115,552. Current data concerning this factor are presented only to help exemplify the separation and characterization of the other novel antibiotic A-4696 factors which constitute the subject matter of the present application.
  • antibiotic A-4696 can also be separated from antibiotic A-4696 by employing TLC and HPLC . These factors are designated C 1b , C 2a , C 2b' and D and are similar in many respects to antibiotic A-4696 factors A, B 1 , B 2 , B 3' C 1a , C 3 , and E l . In addition there may be other as yet undetected factors in the antibiotic A-4696 complex.
  • the minor factors have not been isolated and purified in sufficient quantity to allow for characterization.
  • the individual antibiotic A-4696 factors are substantially differentiated by their neutral sugar components which are attached to the pseudo-aglycone at unknown positions.
  • Antibiotic A-4696 factor B 1 as the hydrochloride salt, is a white crystalline compound which is soluble in water and hydroxylic and polar solvents, and insoluble in solvents such as ether, chloroform, benzene, acetone, aliphatic hydrocarbons, chlorinated hydrocarbons and the like. It is stable in aqueous solution over a pH range of about 4 to about 9 at temperatures up to about 27°C.
  • Microanalysis of antibiotic A-4696 factor B 1 hydrochloride of antibiotic A-4696 shows the following approximate elemental composition with oxygen comprising the remainder: C 51.51; H 5.25; N 4.88; Cl 4.62.
  • the approximate molecular weight, theoretically determined by combining the molecular weights of the pseudo-aglycone and the known attached sugars, is 1954.
  • the ultraviolet absorption maximum of antibiotic A-4696 factor B 1 hydrochloride in water is at 280 nm with an of 42.8.
  • Antibiotic A-4696 factor B 2 is a white crystalline compound which is soluble in water and hydroxylic and polar solvents, and insoluble in solvents such as ether, chloroform, benzene, acetone, aliphatic hydrocarbons, chlorinated hydrocarbons and the like. It is stable in aqueous solution over a pH range of about 4 to about 9 at temperatures up to about 27°C.
  • the ultraviolet absorption maximum of antibiotic A-4696 factor B 2 hydrochloride in water is at 280 nm with an of 44.7.
  • Antibiotic A-4696 factor B 3 is a white crystalline compound which is soluble in water and hydroxylic and polar solvents, and insoluble in solvents such as ether, chloroform, benzene, acetone, aliphatic hydrocarbons, chlorinated hydrocarbons and the like. It is stable in aqueous solution over a pH range of about 4 to about 9 at temperatures up to about 27°C.
  • Microanalysis of antibiotic A-4696 factor B 3 hydrochloride shows the following approximate elemental composition with oxygen comprising the remainder: C 51.84; H 4.74; N 5.83; Cl 5.57.
  • the approximate molecular weight theoretically determined by combining the molecular weights of the pseudo-aglycone and the known attached sugars, is 1808.
  • the ultraviolet absorption maximum of antibiotic A-4696 factor B 3 hydrochloride in water is at 280 nm with an of 46.3.
  • Antibiotic A-4696 factor C 1a is a white crystalline compound which is soluble in water and hydroxylic and polar solvents, and insoluble in solvents such as ether, chloroform, benzene, acetone, aliphatic hydrocarbons, chlorinated hydrocarbons and the like. It is stable in aqueous solution over a pH range of about 4 to about 9 at temperatures up to about 27°C.
  • the ultraviolet absorption maximum of antibiotic A-4696 factor C 1a hydrochloride in water is at 279 nm with an of 47.9.
  • Antibiotic A-4696 factor C is a white crystalline compound which is soluble in water and hydroxylic and polar solvents, and insoluble in solvents such as ether, chloroform, benzene, acetone, aliphatic hydrocarbons, chlorinated hydrocarbons and the like. It is stable in aqueous solution over a pH range of about 4 to about 9 at temperatures up to about 27°C.
  • Microanalysis of antibiotic A-4696 factor C 3 hydrochloride shows the following approximate elemental composition with oxygen comprising the remainder: C, 51.73; H, 4.69; N, 5.94; Cl, 6.02.
  • the ultraviolet absorption maximum of antibiotic A-4696 factor C 3 hydrochloride in water is at 280 nm with an of 47.9.
  • Antibiotic A-4696 factor E 1 as the hydrochloride salt, is a white crystalline compound which is soluble in water and hydroxylic and polar solvents, and insoluble in solvents such as ether, chloroform, benzene, acetone, aliphatic hydrocarbons, chlorinated hydrocarbons and the like. It is stable in aqueous solution over a pH range of about 4 to about 9 at temperatures up to about 27°C.
  • the ultraviolet absorption maximum of antibiotic A-4696 factor E 1 hydrochloride in water is at 279 nm with an of 39.9.
  • antibiotic activity of antibiotic A-4696 factor B 1 , B 2 , B 31 C 1a , C 3 , or E 1 hydrochloride has been established as being substantially the same as that exhibited by antibiotic A-4696 (disclosed in U.S. Patent 4,115,552) against Bacillus subtilis.
  • antibiotic A-4696 factors B 1 , B 2 , B 3 , C 1a , C 3 , and E 1 can be prepared with mineral acids such as hydrochloric, hydrobromic, sulfonic, phosphoric, and the like.
  • the antibiotic salts of such acids can be prepared, for example, by acidifying a solution of the antibiotic free-base with the desired acid and then precipitating the salt by introducing acetone to the solution.
  • the salts can likewise be prepared in certain instances by ion exchange on an ion exchange column. Other known methods for the preparation of antibiotic salts can also be employed.
  • the novel antibiotic A-4696 factors have an inhibiting action on the growth of many microbial organisms which are pathogenic to man, animals and plants, and are therefore useful in suppressing the growth of such organisms.
  • the levels at which antibiotic A-4696 factors B 1 , B 2 , B 3 , C la , C3, and E1 as hydrochlorides show inhibition against the growth of illustrative organisms are set forth numerically in Tables 1 and 2 below. The inhibition levels were determined by the agar-dilution test and are stated in terms of the minimum inhibitory concentration (MIC), microgram(s) per milliliter (mcg./ml.).
  • test organism In the agar-dilution test the test organism is streaked or implanted on agar plates containing various concentrations of antibiotic A-4696 factor hydrochlorides in the agar. The test plates are incubated at 37°C. for 48 hours, and the MIC is determined as the plate at the lowest concentration of the antibiotic where growth of the test organism is inhibited.
  • Antibiotic A-4696 factors B 1 , B 2 , B 3 , C 1a , C3, and E 1 hydrochlorides are effective antibacterial and antimicrobial agents which are useful for combating pathogenic microorganisms generally.
  • the incorporation of antibiotic A-4696 factor B 1, B 2' B 3 , C 1a , C 3 , or E l or the acid addition salts thereof, into an appropriate toothpaste, gel, powder, or the like, or a suitable mouthwash, or other oral hygiene preparation can provide an effective method for inhibiting the development of dental caries and periodontal disease which are associated with bacterial action.
  • a solution of one or more antibiotic A-4696 factors or an acid addition salt thereof at an appropriate concentration can be applied to the surface of the gums and teeth with a suitable swab.
  • Antibiotic A-4696 factors B 1 , B 2' B 3' C la' C 3 , and E 1 also show growth promotant activity and accelerate the growth rate and increase feed efficiency in poultry, swine, sheep, and beef cattle.
  • the daily ingestion by poultry and swine of one or more antibiotics of the present invention in an amount of about 0.5 mg. to about 25 mg./kg. of body weight results in faster growth and greater feed efficiency than that registered by animals fed the same basal ration without the active agent.
  • the term "basal ration" refers to the total feed intake of the animal and consists of the various feedstuffs, concentrates, supplements, minerals, vitamins or medicated premixes, roughages, and the like containing the dietary requirements of the animal. Typical basal rations for poultry and swine are found in U.S. Patent 4,115,552.
  • antibiotic A-4696 factor B l , B 2 , B 3 , C 1a , C3, or E 1 , or a suitable derivative or mixture thereof is administered orally in a suitable feed in an amount of about 2 to 200 grams per ton of total feed to provide for increased feed efficiency and growth promotion activity.
  • the addition of the active antibiotic A-4696 factors of this invention to animal feed is preferably accomplished by preparing an appropriate feed premix (such as, for example, is disclosed in U.S. Patent 4,115,552) containing about 1 to 200 grams of antibiotic A -4696 factor B 1 , B 2 ' B 3 , C 1a , C 3 , or E 1 , or a suitable derivative or mixture therof, per kilogram of premix.
  • an intermediate concentrate or feed supplement containing the active agent can be blended into the feed.
  • novel antibiotic A-4696 factors B 1 , B 2' B 3 , C 1a , C 3 , and E 1 are useful in several different ways, they are particularly effective as antibiotics. Substances which exhibit this type of activity are always in demand for the treatment of microbially related health problems generally.
  • novel antibiotic factors of this invention are isolated from antibiotic A-4696, the latter being produced by culturing one of several strains of Actinoplanes under aerobic conditions in a suitable culture medium until the culture medium contains substantial antibiotic activity.
  • the antibiotic factors can be recovered by employing various appropriate isolation and purification procedures.
  • the microorganism used for the production of antibiotic A-4696 has been identified as a strain of Actinoplanes missouriensis of the family Actinoplanaceae.
  • the Actinoplanaceae are a family of microorganisms of the order Actinomycetales, having been first described by Dr. John N. Couch, Jour. Elisha Mitchell Sci. Soc., 65, 315-318 (1949); and 66, 87-92 (1950); Trans. New York Acad. Sci., 16, 315-318 (1954); Jour. Elisha Mitchell Sci. Soc., 71, 148-155 and 269 (1955); Bergey's Manual of Determinative Bacteriology, 7th Edition, 825-829 (1957); and Jour. Elisha Mitchell Sci. Soc., 79, 53-70 (1963).
  • Strain ATCC 31682 is useful for production of antibiotic A-4696 for subsequent isolation of antibiotic A-4696 factors B1 and C 1a ; strain ATCC 31680 for isolation of antibiotic A-4696 factors 3 2 and C 3 ; and strain ATCC 31683 for isolation of antibiotic A-4696 factors B 3 and E 1 .
  • Actinoplanes misseuriensis strains ATCC 31580, ATCC 31682, and ATCC 31683 are characterized by the physical and cultural properties set forth in the following paragraphs. Deposits of all three of these strains were made in the American Type Culture Collection, Rockville, Maryland, U.S.A., on 26th August-1980 whence they are available to the public.
  • the three strains are derived by a series of mutations from ATCC 23342 which was previously disclosed in U.S. Patent 4,115,552.
  • the present strains produce a similar substrate or mycelium and their morphology is substantially indistinguishable from that of the parental strain. Neither aerial, secondary mycelia, nor sporangia are observed and moreover, techniques such as growth on pollen grains, likewise fails to yield any sporangia.
  • Strain ATCC 31680 has an orange colored mycelium ranging from moderate to brownish orange to strong orange depending upon the medium. Strains ATCC 31682 and ATCC 31683 have no such distinctive color and show mycelia which are yellowish gray.
  • Actinoplanes missouriensis strains ATCC 31680, ATCC 31682, and ATCC 31683 can be grown in a culture medium to produce antibiotic A-4696 for subsequent isolation of the antibiotic A-4696 factors.
  • the culture medium can be any one of a number of different media. However for economy in production, maximum yield, and ease of isolation of the antibiotic, certain culture media are preferred.
  • starch is one of the preferred sources of carbohydrate
  • yeast is one of the preferred nitrogen sources.
  • Other carbohydrate sources which can be used include molasses, glucose, dextrin, glycerol, and the like. Nitrogen sources also include amino acid mixtures, peptones, and the like.
  • Nutrient inorganic salts to be incorporated in the culture medium can include the customary salts capable of yielding sodium, potassium, ammonia, calcium, phosphate, chloride, sulfate, and like ions. Additionally, sources of growth factors, such as distillers' solubles and yeast extracts, can be included with beneficial effect on the production of antibiotic A-4696 factors.
  • the organisms used to produce antibiotic A-4696 for subsequent isolation of antibiotic A-4696 factors B 1 , B 2 , B 3 , C 1a , C3' and E 1 can be grown over a relatively wide pH range. However it is desirable to culture the organisms in a medium with a pH between about 6.5 and 7.0. As with other Actinomycetes, the pH of the growing medium gradually changes during the growth period, the pH at the end of the fermentation period usually ranging from about 6.5 to 7.5.
  • Submerged aerobic cultural conditions are preferred for the production of the antibiotic A-4696 factors.
  • Relatively small amounts of the antibiotics can be produced by shake flask culture; however, for the preparation of large amounts, submerged aerobic culture in sterile tanks is preferred.
  • the culture medium in the sterile tank can be inoculated with a mycelial fragment suspension.
  • a vegetative inoculum of the organism by inoculating a relatively small quantity of culture medium with the mycelial fragments of the organism, and when a young active vegetative inoculum is obtained, to aseptically transfer it to the large tank.
  • the medium in which the vegetative inoculum is grown can be the same as that utilized for large scale production of the antibiotic A-4696 factors, although other media can be employed.
  • the antibiotic A-4696 factor producing Actinoplanes missouriensis strains ATCC 31680, ATCC 31682, and ATCC 31683 grow at temperatures between 20° and 40°C. The largest amounts of A-4696 factors appear to be produced at a temperature of about 30°C.
  • the volume of air sparged into the culture medium varies from about 0.1 to about 1.0 volume of air per minute per volume of culture medium.
  • the most efficient growth and antibiotic production are achieved when the volume of air is at least 1/2 volume of air per minute per volume of culture medium.
  • the rate of production of antibiotic A-4696 factors and the concentration of antibiotic activity in the culture medium can be followed during the growth period by testing samples of the fermentation broth for antibiotic activity against organisms known to be susceptible to the antibiotic.
  • One such assay organism useful to illustrate the present invention is Bacillus subtilis.
  • the bioassay can be carried out by the standard cup-plate methods, or by the paper disc assay on agar plates.
  • maximum production of the antibiotic occurs within about 4 to 6 days in shake flasks or submerged aerobic culture fermentations.
  • Antibiotic A-4696 for subsequent isolation of antibiotic A-4696 factors B 1 , B 2 , B 3' C 1a , C 3 , and E l can be isolated from the culture medium and separated from other substances which may be present by adsorptive and extractive techniques. Adsorptive techniques are preferred because such procedures avoid the use of large volumes of solvents required in extraction processes.
  • the slant inoculated with ATCC 31682 was then incubated for 6 days at 30°C.
  • the culture does not sporulate so it is necessary to macerate the mycelial mat with a sterile pipette.
  • the macerated mature culture was covered with sterile distilled water and scraped carefully with the pipette or a sterile rod to obtain a mycelial suspension.
  • the suspension thus obtained was used to inoculate 100 ml. of a sterile vegetative medium having the following composition:
  • the inoculated vegetative medium was grown for 48 hours at 30°C. on a rotary shaker operating at 250 rpm. Ten ml. of the inoculated vegetative medium was inoculated into 100 ml. of a sterile "bump" medium of the following composition.
  • the inoculated "bump” medium was incubated for 24 hours at 30°C. with constant shaking on a rotary shaker operating at 250 rpm.
  • the production fermentation was shaken for about 96 hours at a temperature of 30°C. on a rotary shaker operating at 250 rpm.
  • the pH at the end of the fermentation cycle was about 8.0.
  • strain ATCC 31683 was used to prepare the "bump" medium according to the teaching disclosed above.
  • Four-tenths ml. of the strain ATCC 31683 "bump" medium was inoculated into 100 ml. portions of a production medium of the composition shown below contained in 500 ml. Erienmeyer flasks, and sterilized at 121°C. for 30 minutes.
  • the production fermentation was shaken for about 96 hours at a temperature of 30°C. on a rotary shaker operating at 250 rpm.
  • the pH at the end of the fermentation cycle was about 8.0.
  • the preparation of the inoculum proceeded through the incubation of the "bump" medium detailed under section A, above.
  • One-hundred ml. of "bump" medium was inoculated into the sterile production medium.
  • the inoculated production medium was allowed to ferment for 4 days at 30°C.
  • the fermentation was aerated with sterile air in an amount of about one-half volume of air per volume of culture medium per minute.
  • the fermenting production medium was agitated with a mixer utilizing an impeller to insure adequate mixing of air with the medium.
  • the pH of the culture medium gradually increased from an initial level cf about 6.5 to about 8.0 as the fermentation proceeded.
  • Fermentation broth (3800 1.) prepared according to the above procedure was filtered after the addition of 5% (wt/vol) filter aid (Celite 545).
  • the filter cake was resuspended in deionized water (3600 1.) and the pH of the aqueous suspension was adjusted to pH 10.5 using aqueous sodium hydroxide.
  • the suspended solids were separated by filtration and washed with water.
  • the filtrate and the washings were combined and the resulting solution was acidified with 20% (wt/vol) aqueous sulfuric acid to pH 4.5.
  • the acidic solution was clarified by filtration using 1% filter aid (Celite 545).
  • the clear solution was passed through a column (1.8 x 5 ft.) containing 350 1.
  • the crude complex (1.0 kg) was slowly added with vigorous stirring to deionized water (1.5 liters). The resulting suspension was stirred for twenty minutes and was subsequently neutralized (pH 7) using a 10% aqueous ammonium hydroxide solution.
  • the insoluble antibiotic A-4696 complex was separated by vacuum filtration, washed with deionized water, and freeze dried. The dried, desalted, complex was recovered in approximately 80% yield (based on bioactivity).
  • the dried, desalted complex (300 g.) was suspended in deionized water (2 liters), and the pH of the suspension was adjusted to pH 2.7 by addition of 3N aqueous hydrochloric acid.
  • the acidified solution was centrifuged for 40 minutes at 2500 rpm.
  • the supernatant was decanted and loaded on a column (8 x 85 cm) containing 6 liters of decolorizing resin (Duolite S761).
  • the activity was eluted with deionized water at a flow rate of 30 ml/min. The elution was monitored by thin layer chromatography.
  • the antibiotic A-4696-containing effluent was concentrated (3 mm., 35°C.) to a volume of 3 liters and freeze dried.
  • the decolorized complex was recovered as a white-to-tan solid in approximately 70% yield (based on bioactivity).
  • the dried, decolorized antibiotic A-4696 complex (10 g.) was dissolved in 100 ml. of deionized water.
  • the resulting aqueous solution was filtered and loaded on a chromatography column (5 x 100 cm.) containing 2 liters of polyamide (Machery & Nagel SC6).
  • the column was eluted with deionized water and 200-300 fractions (25 ml. each) were collected. The elution was monitored by UV-activity and by thin layer chromatography. Fractions were combined according to TLC identity and freeze dried. For some of the separations it was necessary to double the column length (200 cm.) by using two of the polyamide columns in line. Additional purification was achieved by repeated chromatography.
  • strain ATCC 31682 when isolation of antibiotic A-4696 factors B1 and C la is desired, using strain ATCC 31680 when isolation of A-4696 factors B 2 and C 3 is desired, and using strain ATCC 31683 when isolation of antibiotic A-4696 factors B 3 and E 1 is desired. While other Actinoplanes strains may be used for isolation of the above aforementioned factors, the strains disclosed are preferred for isolation of the antibiotic A-4696 factors claimed herein.
  • Antibiotic A-4696 (300 g. prepared according to the teaching of Example 1, A-D) was suspended in deionized water (2 liters), and the pH of the suspension was adjusted to pH 2.7 by addition of 3N aqueous sulfuric acid. The acidified solution was centrifuged for 40 minutes at 2500 rpm. The supernatant was decanted and loaded on a column (8 x 85 cm) containing 6 liters of decolorizing resin (Duolite S761). The activity was eluted with deionized water at a flow rate of 30 ml./min. The elution was monitored by thin layer chromatography.
  • the antibiotic A-4696-containing effluent was concentrated (3 mm., 35°C.) to a volume of 3 liters and freeze dried.
  • the decolorized complex was recovered as a white-to-tan solid in approximately 70% yield (based on bioactivity).
  • the individual A-4696 factors B 1 , B 2' B 3 , C 1a , C 3 , and E 1 sulfates were isolated according to the teaching of Example 1, F.

Abstract

Antibiotic A-4696 factors B1, B2, B3, C1a, C3, and E1 are isolated from antibiotic A-4696, the latter being produced by Actinoplanes missouriensis strains ATCC 31680, ATCC 31682, or ATC 31683 under submerged aerobic conditions in a culture medium and isolated from the fermentation broth by absorption on an ion exchange resin and eluted therefrom at pH 10.5 with sodium hydroxide. The novel factors are separated by thin layer chromatography and high pressure liquid chromatography and have antimicrobial and growth promotant activity.

Description

  • This invention concerns novel factors B1, B2, B 3' C1a, C 3 and E1 of actaplanin antibiotic A-4696. They are effective antibacterial and antimicrobial agents as well as growth promotant agents in poultry, swine, sheep and beef cattle.
  • The present invention is related generally to the inventions disclosed in U.S. Patent 3,952,095 issued April 20, 1976, for novel antibiotic and a process for the production thereof, U.S. Patent No. 4,064,233 issued December 20, 1977, for antibiotic A-4696, and U.S. Patent 4,115,552 issued September 19, 1978, for factor A and B of antibiotic A-4696.
  • Factor B of antibiotic A-4696, described in U.S. Patent 4,064,233 and U.S. Patent 4,115,552, is not the same as any of the factors claimed in the present application. Furthermore, none of the present antibiotic A-4696 factors were known, appreciated, or even suspected prior to the present invention.
  • It has now been discovered that the novel actaplanin antibiotic A-4696 factors B1, B2, B3' Cla' C3 and El, as described herein below, are effective antibacterial and antimicrobial agents. These factors accelerate the growth rate in animals and increase feed efficiency in poultry, swine, sheep and beef cattle.
  • The antibiotic A-4696 factors B1, B2' B3, C1a, C3 and E1 are isolated from the A-4696 complex which is produced by culturing a microorganism Actinoplanes missouriensis ATCC 31680, ATCC 31682 or ATCC 31683 in a culture medium containing assimilable sources of carbohydrate, nitrogen and inorganic salts under submerged aerobic fermentation conditions until a substantial amount of antibiotic activity is produced.
  • The method for increasing the feed utilization efficiency in ruminant animals is accomplished by administering to the ruminant animals a growth promotant amount of the antibiotic A-4696 complex or the A-4696 factors B1, B2, B3' Cla' C3 and/or E1 or a pharmaceutically acceptable acid addition salt thereof in the form of a feed, feed premix or feed supplement.
  • The method for promoting the growth of chickens comprises administering to the chickens either in their diet or drinking water a growth promotant amount of the antibiotic A-4696 complex or the novel factors B1, B2, B3' C1a, C3 and/or E1, or a pharmaceutically acceptable salt thereof.
  • The present invention relates to novel factors B1, B2, B3, C1a, C3, and El, of actaplanin antibiotic A-4696. In accordance with the present invention novel factors of antibiotic A-4696 are isolated from antibiotic A-4696, the latter being produced by culturing a microorganism belonging to the genus Actinoplanes in a nutrient medium until substantial antibacterial activity is detected in the culture medium.
  • - High performance liquid chromatography (HPLC) reveals that the antibiotic A-4696 complex as disclosed in related applications listed herein above, comprises several heretofore unknown factors designated as B1, B 2r B 3' C1a, and C3. An additional factor, designated as E1, can also be isolated from the antibiotic A-4696 complex and may represent a degradation product. The chemical, physical, and biological properties of the factors indicate that they are new antibiotics and, except possibly for factor E1, that they are composed of the same peptide core (aglycone) and amino sugar, and varying amounts of glucose, mannose, and rhamnose. While factor E1 is similar in most respects to the other factors, it is possible that it possesses a somewhat modified peptide core. Bioautography of aglycone formation during hydrolysis of both the A-4696 complex and the individual factors shows that within a short time a simple mixture of antimicrobially active pseudo-aglycone and aglycone is obtained. It is possible that the site of antimicrobial activity of the A-4696 complex and individual factors resides in the peptide pseudo-aglycone, with the factors being substantially differentiated by differences in their neutral sugar composition. The attached sugars may function chiefly to modulate solubility and other important pharmaco- dynamic parameters. However, the manner in which the antibiotic factors claimed herein function or are produced does not constitute a part of the invention, and applicant does not intend to be limited in any way by the postulated mode of action stated herein.
  • The antibiotic factors of this invention are isolated from antibiotic A-4696 which is produced by culturing the organism Actinoplanes missouriensis in an aqueous nutrient medium under submerged aerobic fermentation conditions. The antibiotic A-4696 complex is first separated from the fermentation broth and then the individual factors are isolated by liquid chromatography. Preferably the antibiotic factors of the present invention are converted to a hydrochloride or sulfate salt.
  • For purposes of the present application, the term 'antibiotic A-4696' is used to designate the actaplanin antibiotic complex, while the various factors isolated from the complex are designated as antibiotic A-4696 factors A, B1, B2' B3' C1a, C3' E1, and so forth. Antibiotic A-4696 and the individual factors isolated therefrom, are highly effective in preventing the growth of microorganisms which are pathogenic to both man and animals. In addition, the antibiotic factors of the present invention have agricultural application as growth promotants in chickens, swine, sheep, and beef cattle.
  • The novel antibiotic factors B1, B2, B 3' C1a, C3, and E1 of antibiotic A-4696 are basic compounds capable of forming salts with suitable acids and are isolated from antibiotic A-4696 which is produced by culturing a microorganism belonging to the species Actinoplanes missouriensis in a nutrient medium until substantial antibacterial activity is detected in the culture medium. The characterization data presented below are for the antibiotic A-4696 factors in the form of their hydrochloride salts, although other pharmaceutically acceptable salts can also be prepared by employing methods known in the art.
  • Silica gel thin layer chromatography (TLC) bioautography and high pressure liquid chromatography (HPLC) reveal that antibiotic A-4696, when subjected to the isolation procedure, yields a mixture of several components which show antibiotic activity. The components, designated as antibiotic A-4696 factors A, B1, B2, B 3' C1a, C3, and E1, can be preparatively separated from antibiotic A-4696 by chromatography through a polyamide column. The chromatography fractions are monitored by UV-activity and thin layer chromatography (TLC) and identical chromatography fractions containing the pure antibiotic A-4696 factor A, Bl, B2, B 3' Clay C3, or El are combined and freeze dried. The identity and purity of the resulting freeze dried chromatography pools can be determined by HPLC.
  • Antibiotic A-4696 factor A was previously isolated and is substantially as disclosed in U.S. Patent 4,115,552. Current data concerning this factor are presented only to help exemplify the separation and characterization of the other novel antibiotic A-4696 factors which constitute the subject matter of the present application.
  • Thin layer chromatography of antibiotic A-4696 with bio-overlay using methanol-chloroform- conc. ammonium hydroxide-sec. butanol-water (50:25: 25:25:10) as the solvent, and Bacillus subtilis as the detection organism, gives the following results:
  • Figure imgb0001
    High pressure liquid chromatography of antibiotic A-4696 at ambient temperature using 2% aqueous acetic acid/ CH3CN (90/10) and 2% aqueous acetic acid/CH3CN (70/30) as the solvents gives the following results:
    Figure imgb0002
  • Several additional minor factors can also be separated from antibiotic A-4696 by employing TLC and HPLC. These factors are designated C1b, C2a, C 2b' and D and are similar in many respects to antibiotic A-4696 factors A, B1, B2, B3' C1a, C3, and El. In addition there may be other as yet undetected factors in the antibiotic A-4696 complex. The minor factors have not been isolated and purified in sufficient quantity to allow for characterization.
  • - When either antibiotic A-4696 or the individual antibiotic A-4696 factors are hydrolyzed under mild acidic conditions (5% methanolic HC1, reflux, 70 minutes) a pseudo-aglycone is produced. The pseudo-aglycone precipitates from the hydrolysis mixture and, in the case of antibiotic A-4696 factors A, B1, B2, B 3' C1a, and C3, has the following structure:
    Figure imgb0003
  • In the case of antibiotic A-4696 factor E1, it is possible but not certain that the above pseudo-aglycone may be somewhat modified.
  • Paper and TLC examination of the hydrolysis filtrates of the antibiotic A-4696 complex and the individual antibiotic A-4696 factors reveals that, in addition to a pseudo-aglycone core, the complex and factors each contain varying amounts of neutral sugars. The identity and molar ratios of the neutral sugars found in antibiotic A-4696 factors A, B1, B2, B3, and C1a are presented as follows:
    Figure imgb0004
  • The individual antibiotic A-4696 factors are substantially differentiated by their neutral sugar components which are attached to the pseudo-aglycone at unknown positions.
  • Antibiotic A-4696 factor B1, as the hydrochloride salt, is a white crystalline compound which is soluble in water and hydroxylic and polar solvents, and insoluble in solvents such as ether, chloroform, benzene, acetone, aliphatic hydrocarbons, chlorinated hydrocarbons and the like. It is stable in aqueous solution over a pH range of about 4 to about 9 at temperatures up to about 27°C.
  • Microanalysis of antibiotic A-4696 factor B1 hydrochloride of antibiotic A-4696 shows the following approximate elemental composition with oxygen comprising the remainder: C 51.51; H 5.25; N 4.88; Cl 4.62. The approximate molecular weight, theoretically determined by combining the molecular weights of the pseudo-aglycone and the known attached sugars, is 1954.
  • The ultraviolet absorption maximum of antibiotic A-4696 factor B1 hydrochloride in water is at 280 nm with an
    Figure imgb0005
    of 42.8.
  • The infrared absorption spectrum of antibiotic A-4696 factor B1 hydrochloride in KBr is shown in Figure 1 of the accompanying drawings. The observed distinguishable absorption maximum over the range of 4000-700 cm 1 are as follows: 3380 broad, 2930, 1731, 1693, 1654, 1637, 1615, 1588, 1577, 1521, 1503, 1488, 1423, 1321, 1289, 1229, 1210, 1178, 1154, 1121, 1076, 1060, 1030, 1012, 982, 880, 842, 831, 810 cm-1.
  • Antibiotic A-4696 factor B2, as the hydrochloride salt, is a white crystalline compound which is soluble in water and hydroxylic and polar solvents, and insoluble in solvents such as ether, chloroform, benzene, acetone, aliphatic hydrocarbons, chlorinated hydrocarbons and the like. It is stable in aqueous solution over a pH range of about 4 to about 9 at temperatures up to about 27°C.
  • Microanalysis of antibiotic A-4696 factor B2 hydrochloride shows the following approximate elemental composition with oxygen comprising the remainder:
    • C 51.96; H 4.67; N 5.72; Cl 5.88. The approximate molecular weight, theoretically determined by combining the molecular weights of the pseudo-aglycone and the known attached sugars, is 1808.
  • The ultraviolet absorption maximum of antibiotic A-4696 factor B2 hydrochloride in water is at 280 nm with an
    Figure imgb0006
    of 44.7.
  • The infrared absorption spectrum of antibiotic A-4696 factor B2 hydrochloride in KBr is shown in Figure 2 of the accompanying drawings. The observed distinguishable absorption maxima over the range of 4000-700 cm-1 are as follows: 3409 broad, 2934, 1730, 1658, 1614, 1588, 1548, 1504, 1498, 1490, 1426, 1290, 1231, 1210, 1179, 1121, 1061, 1031, 1017, 987, 903, 884, 818 cm-1.
  • Antibiotic A-4696 factor B3, as the hydrochloride salt, is a white crystalline compound which is soluble in water and hydroxylic and polar solvents, and insoluble in solvents such as ether, chloroform, benzene, acetone, aliphatic hydrocarbons, chlorinated hydrocarbons and the like. It is stable in aqueous solution over a pH range of about 4 to about 9 at temperatures up to about 27°C.
  • Microanalysis of antibiotic A-4696 factor B3 hydrochloride shows the following approximate elemental composition with oxygen comprising the remainder: C 51.84; H 4.74; N 5.83; Cl 5.57. The approximate molecular weight, theoretically determined by combining the molecular weights of the pseudo-aglycone and the known attached sugars, is 1808.
  • The ultraviolet absorption maximum of antibiotic A-4696 factor B3 hydrochloride in water is at 280 nm with an
    Figure imgb0007
    of 46.3.
  • The infrared absorption spectrum of antibiotic A-4696 factor B3 hydrochloride in KBr is shown in Figure 3 of the accompanying drawings. The observed distinguishable absorption maxima over the range of 4000-700 cm-1 are as follows: 3394 broad, 2938, 1733, 1697, 1675, 1656, 1638, 1614, 1591, 1515, 1504, 1489, 1427, 1359, 1291, 1228, 1209, 1180, 1120, 1072, 1051, 1018, 985, 903, 882, 846, 816 cm-1.
  • Antibiotic A-4696 factor C1a, as the hydrochloride salt, is a white crystalline compound which is soluble in water and hydroxylic and polar solvents, and insoluble in solvents such as ether, chloroform, benzene, acetone, aliphatic hydrocarbons, chlorinated hydrocarbons and the like. It is stable in aqueous solution over a pH range of about 4 to about 9 at temperatures up to about 27°C.
  • Microanalysis of antibiotic A-4696 factor C1a hydrochloride shows the following approximate elemental composition with oxygen comprising the remainder:
    • C 53.05; H 4.74; N 5.83; Cl 5.39. The approximate molecular weight theoretically determined by combining the molecular weight of the pseudo-aglycone and the known attached sugars, is 1792.
  • The ultraviolet absorption maximum of antibiotic A-4696 factor C1a hydrochloride in water is at 279 nm with an
    Figure imgb0008
    of 47.9.
  • The infrared absorption spectrum of antibiotic A-4696 factor C1a hydrochloride in KBr is shown in Figure 4 of the accompanying drawings. The observed distinguishable absorption maxima over the range of 4000-700 cm 1 are as follows: 3380 broad, 2931, 1734, 1650, 1616, 1591, 1505, 1491, 1427, 1359, 1290, 1228, 1213, 1177, 1123, 1072, 1061, 1032, 1017, 987, 903, 832, 814, 715 cm-1.
  • Antibiotic A-4696 factor C,, as the hydrochloride salt, is a white crystalline compound which is soluble in water and hydroxylic and polar solvents, and insoluble in solvents such as ether, chloroform, benzene, acetone, aliphatic hydrocarbons, chlorinated hydrocarbons and the like. It is stable in aqueous solution over a pH range of about 4 to about 9 at temperatures up to about 27°C.
  • Microanalysis of antibiotic A-4696 factor C3 hydrochloride shows the following approximate elemental composition with oxygen comprising the remainder: C, 51.73; H, 4.69; N, 5.94; Cl, 6.02.
  • The ultraviolet absorption maximum of antibiotic A-4696 factor C3 hydrochloride in water is at 280 nm with an
    Figure imgb0009
    of 47.9.
  • The infrared absorption spectrum of antibiotic A-4696 factor C3 hydrochloride in KBr is shown in Figure 5 of the accompanying drawings. The observed distinguishable absorption maxima over the range of 4000-700 cm-1 are as follows: 3378 broad, 2925, 1728, 1689, 1658, 1637, 1616, 1589, 1579, 1573, 1546, 1536, 1529, 1523, 1503, 1489, 1474, 1457, 1426, 1421, 1397, 1387, 1286, 1231, 1206, 1121, 1075, 1062, 1028, 1C12, 987, 965, 949, 878, 840, 816, 769, 708 cm-1.
  • Antibiotic A-4696 factor E1, as the hydrochloride salt, is a white crystalline compound which is soluble in water and hydroxylic and polar solvents, and insoluble in solvents such as ether, chloroform, benzene, acetone, aliphatic hydrocarbons, chlorinated hydrocarbons and the like. It is stable in aqueous solution over a pH range of about 4 to about 9 at temperatures up to about 27°C.
  • Microanalysis of antibiotic A-4696 factor E1 hydrochloride shows the following approximate elemental composition with oxygen comprising the remainder:
    • C 50.71; H 4.70; N 9.01; Cl 1.84.
  • The ultraviolet absorption maximum of antibiotic A-4696 factor E1 hydrochloride in water is at 279 nm with an
    Figure imgb0010
    of 39.9.
  • The infrared absorption spectrum of antibiotic A-4696 factor E1 hydrochloride in KBr is shown in Figure 6 of the accompanying drawings. The observed distinguishable absorption maxima over the range of 4000-700cm-1 are as follows: 3394 broad, 2933, 1657, 1636, 1610, 1589, 1538, 1511, 1505, 1453, 1424, 1393, 1369, 1328, 1320, 1291, 1232, 1212, 1178, 1120, 1075, 1061, 1031, 1018, 986, 973, 904, 878, 847, 813, 770, 752, 738, 714 cm-1.
  • The antibiotic activity of antibiotic A-4696 factor B1, B2, B31 C1a, C3, or E1 hydrochloride has been established as being substantially the same as that exhibited by antibiotic A-4696 (disclosed in U.S. Patent 4,115,552) against Bacillus subtilis.
  • By employing methods known in the art, pharmaceutically acceptable salts of antibiotic A-4696 factors B1, B2, B3, C1a, C3, and E1 can be prepared with mineral acids such as hydrochloric, hydrobromic, sulfonic, phosphoric, and the like. The antibiotic salts of such acids can be prepared, for example, by acidifying a solution of the antibiotic free-base with the desired acid and then precipitating the salt by introducing acetone to the solution. The salts can likewise be prepared in certain instances by ion exchange on an ion exchange column. Other known methods for the preparation of antibiotic salts can also be employed.
  • The novel antibiotic A-4696 factors have an inhibiting action on the growth of many microbial organisms which are pathogenic to man, animals and plants, and are therefore useful in suppressing the growth of such organisms. The levels at which antibiotic A-4696 factors B1, B2, B3, Cla, C3, and E1 as hydrochlorides show inhibition against the growth of illustrative organisms are set forth numerically in Tables 1 and 2 below. The inhibition levels were determined by the agar-dilution test and are stated in terms of the minimum inhibitory concentration (MIC), microgram(s) per milliliter (mcg./ml.).
  • In the agar-dilution test the test organism is streaked or implanted on agar plates containing various concentrations of antibiotic A-4696 factor hydrochlorides in the agar. The test plates are incubated at 37°C. for 48 hours, and the MIC is determined as the plate at the lowest concentration of the antibiotic where growth of the test organism is inhibited.
  • The results are as follows:
    Figure imgb0011
    Figure imgb0012
    Figure imgb0013
    Figure imgb0014
    Figure imgb0015
    Figure imgb0016
    Figure imgb0017
  • Antibiotic A-4696 factors B1, B2, B3, C1a, C3, and E1 hydrochlorides, as seen from the above data, are effective antibacterial and antimicrobial agents which are useful for combating pathogenic microorganisms generally. In addition, the incorporation of antibiotic A-4696 factor B1, B2' B3, C1a, C3, or El or the acid addition salts thereof, into an appropriate toothpaste, gel, powder, or the like, or a suitable mouthwash, or other oral hygiene preparation, can provide an effective method for inhibiting the development of dental caries and periodontal disease which are associated with bacterial action. Alternatively, a solution of one or more antibiotic A-4696 factors or an acid addition salt thereof at an appropriate concentration, can be applied to the surface of the gums and teeth with a suitable swab.
  • Antibiotic A-4696 factors B 1, B 2' B 3' C la' C3, and E1 also show growth promotant activity and accelerate the growth rate and increase feed efficiency in poultry, swine, sheep, and beef cattle. For example, the daily ingestion by poultry and swine of one or more antibiotics of the present invention in an amount of about 0.5 mg. to about 25 mg./kg. of body weight, results in faster growth and greater feed efficiency than that registered by animals fed the same basal ration without the active agent. The term "basal ration" refers to the total feed intake of the animal and consists of the various feedstuffs, concentrates, supplements, minerals, vitamins or medicated premixes, roughages, and the like containing the dietary requirements of the animal. Typical basal rations for poultry and swine are found in U.S. Patent 4,115,552.
  • In an important embodiment of the present invention, antibiotic A-4696 factor Bl, B2, B3, C1a, C3, or E1, or a suitable derivative or mixture thereof, is administered orally in a suitable feed in an amount of about 2 to 200 grams per ton of total feed to provide for increased feed efficiency and growth promotion activity. The addition of the active antibiotic A-4696 factors of this invention to animal feed is preferably accomplished by preparing an appropriate feed premix (such as, for example, is disclosed in U.S. Patent 4,115,552) containing about 1 to 200 grams of antibiotic A-4696 factor B1, B 2' B3, C1a, C3, or E1, or a suitable derivative or mixture therof, per kilogram of premix. The completed premix is then incorporated into the final ration. Alternatively, an intermediate concentrate or feed supplement containing the active agent can be blended into the feed.
  • While the novel antibiotic A-4696 factors B1, B2' B3, C1a, C3, and E1 are useful in several different ways, they are particularly effective as antibiotics. Substances which exhibit this type of activity are always in demand for the treatment of microbially related health problems generally.
  • The novel antibiotic factors of this invention are isolated from antibiotic A-4696, the latter being produced by culturing one of several strains of Actinoplanes under aerobic conditions in a suitable culture medium until the culture medium contains substantial antibiotic activity. The antibiotic factors can be recovered by employing various appropriate isolation and purification procedures.
  • The microorganism used for the production of antibiotic A-4696 has been identified as a strain of Actinoplanes missouriensis of the family Actinoplanaceae. The Actinoplanaceae are a family of microorganisms of the order Actinomycetales, having been first described by Dr. John N. Couch, Jour. Elisha Mitchell Sci. Soc., 65, 315-318 (1949); and 66, 87-92 (1950); Trans. New York Acad. Sci., 16, 315-318 (1954); Jour. Elisha Mitchell Sci. Soc., 71, 148-155 and 269 (1955); Bergey's Manual of Determinative Bacteriology, 7th Edition, 825-829 (1957); and Jour. Elisha Mitchell Sci. Soc., 79, 53-70 (1963).
  • Biologically pure cultures of the Actinoplanes missouriensis strains useful for the production of antibiotic A-4696 for subsequent isolation of antibiotic A-4696 factors B1, B2, B3' C1a, C3, and E 1 have been deposited and made part of the stock culture collection of the American Type Culture Collection, Rockville, Maryland, from which they are available to the public without restriction under the numbers ATCC 31680, ATCC 31682, and ATCC 31683. Strain ATCC 31682 is useful for production of antibiotic A-4696 for subsequent isolation of antibiotic A-4696 factors B1 and C1a; strain ATCC 31680 for isolation of antibiotic A-4696 factors 32 and C3; and strain ATCC 31683 for isolation of antibiotic A-4696 factors B3 and E1.
  • Actinoplanes misseuriensis strains ATCC 31580, ATCC 31682, and ATCC 31683 are characterized by the physical and cultural properties set forth in the following paragraphs. Deposits of all three of these strains were made in the American Type Culture Collection, Rockville, Maryland, U.S.A., on 26th August-1980 whence they are available to the public.
  • The three strains are derived by a series of mutations from ATCC 23342 which was previously disclosed in U.S. Patent 4,115,552. The present strains produce a similar substrate or mycelium and their morphology is substantially indistinguishable from that of the parental strain. Neither aerial, secondary mycelia, nor sporangia are observed and moreover, techniques such as growth on pollen grains, likewise fails to yield any sporangia.
  • The main differences between the present strains are the cultural characteristics, specifically the pigmentation of the primary mycelia. Strain ATCC 31680 has an orange colored mycelium ranging from moderate to brownish orange to strong orange depending upon the medium. Strains ATCC 31682 and ATCC 31683 have no such distinctive color and show mycelia which are yellowish gray.
  • The methods used for the taxonomic studies of strains ATCC 31680, ATCC 31682, and ATCC 31683 are well known to those skilled in the art and in large part are methods recommended for the International Streptomyces Project (ISP), described by Shirling and Gottlieb, 1966, Intern. J. of Systematic Bacteriol. 16(3):313-340. Enzyme assays were carried out according to the methods of Blazevic and Ederer, 1975, Principles of Biochemical Tests in Diagnostic Microbiology, John Wiley and Sons, Inc., New York, and color names, abbreviations, and numbers were assigned using the ISCC-NBS method of Kelly and Judd, 1976, The ISCC-NBS Centroid Color Charts Standard Sample No. 2106, U.S. Dept. of Commerce, National Bureau of Standards, Washington D.C. Lysozyme resistance and the decomposition of casein, esculin, hypoxanthine, tyrosine, and xanthine were measured using the procedure of Berg, 1973, Appl. Microbiol. 25:665-681. Carbon utilization studies were also completed and are scored as follows:
    • ++ = equal to or > glucose control; positive utilization
    • + = < glucose control, > no carbon control; positive utilization
    • (+) = growth questionable; doubtful utilization - = no growth; negative utilization
  • Accordingly a taxonomic description, including both the cultural and physiological characteristics, of the Actinoplanes strains of the present invention is given in tabular form below.
  • General Culture And Physiological Characteristics Of Actinoplanes Strain ATCC 31680
  • Figure imgb0018
    Figure imgb0019
    Figure imgb0020
    Figure imgb0021
  • Carbon utilization on ISP medium no. 9* with:
    Figure imgb0022
    Figure imgb0023
    Figure imgb0024
    Figure imgb0025
    Figure imgb0026
  • Antibiotic sensitivity:
    Figure imgb0027
    Figure imgb0028
  • Carbon utilization on
  • ISP medium no. 9* with:
    Figure imgb0029
    Figure imgb0030
    Figure imgb0031
    Figure imgb0032
    Figure imgb0033
  • Antibiotic sensitivity:
    Figure imgb0034
  • Carbon utilization on
  • ISP medium no. 9* with:
    Figure imgb0035
  • As previously noted, Actinoplanes missouriensis strains ATCC 31680, ATCC 31682, and ATCC 31683 can be grown in a culture medium to produce antibiotic A-4696 for subsequent isolation of the antibiotic A-4696 factors. The culture medium can be any one of a number of different media. However for economy in production, maximum yield, and ease of isolation of the antibiotic, certain culture media are preferred. Thus, for example, starch is one of the preferred sources of carbohydrate, and yeast is one of the preferred nitrogen sources. Other carbohydrate sources which can be used include molasses, glucose, dextrin, glycerol, and the like. Nitrogen sources also include amino acid mixtures, peptones, and the like.
  • Nutrient inorganic salts to be incorporated in the culture medium can include the customary salts capable of yielding sodium, potassium, ammonia, calcium, phosphate, chloride, sulfate, and like ions. Additionally, sources of growth factors, such as distillers' solubles and yeast extracts, can be included with beneficial effect on the production of antibiotic A-4696 factors.
  • As is necessary for the growth and development of other microorganisms, essential trace elements should also be included in the culture medium for growing the Actinoplanes strains employed in this invention. Such trace elements are commonly supplied as impurities incidental to the addition of the other constituents of the medium.
  • The organisms used to produce antibiotic A-4696 for subsequent isolation of antibiotic A-4696 factors B1, B 2, B3, C1a, C3' and E1 can be grown over a relatively wide pH range. However it is desirable to culture the organisms in a medium with a pH between about 6.5 and 7.0. As with other Actinomycetes, the pH of the growing medium gradually changes during the growth period, the pH at the end of the fermentation period usually ranging from about 6.5 to 7.5.
  • Submerged aerobic cultural conditions are preferred for the production of the antibiotic A-4696 factors. Relatively small amounts of the antibiotics can be produced by shake flask culture; however, for the preparation of large amounts, submerged aerobic culture in sterile tanks is preferred. The culture medium in the sterile tank can be inoculated with a mycelial fragment suspension.
  • Accordingly, it is desirable to produce a vegetative inoculum of the organism by inoculating a relatively small quantity of culture medium with the mycelial fragments of the organism, and when a young active vegetative inoculum is obtained, to aseptically transfer it to the large tank. The medium in which the vegetative inoculum is grown can be the same as that utilized for large scale production of the antibiotic A-4696 factors, although other media can be employed.
  • The antibiotic A-4696 factor producing Actinoplanes missouriensis strains ATCC 31680, ATCC 31682, and ATCC 31683, grow at temperatures between 20° and 40°C. The largest amounts of A-4696 factors appear to be produced at a temperature of about 30°C.
  • Sterile air is blown through the culture medium in the submerged aerobic culture process. The volume of air sparged into the culture medium varies from about 0.1 to about 1.0 volume of air per minute per volume of culture medium. The most efficient growth and antibiotic production are achieved when the volume of air is at least 1/2 volume of air per minute per volume of culture medium.
  • The rate of production of antibiotic A-4696 factors and the concentration of antibiotic activity in the culture medium can be followed during the growth period by testing samples of the fermentation broth for antibiotic activity against organisms known to be susceptible to the antibiotic. One such assay organism useful to illustrate the present invention is Bacillus subtilis. The bioassay can be carried out by the standard cup-plate methods, or by the paper disc assay on agar plates.
  • Generally, maximum production of the antibiotic occurs within about 4 to 6 days in shake flasks or submerged aerobic culture fermentations.
  • Antibiotic A-4696 for subsequent isolation of antibiotic A-4696 factors B1, B2, B3' C1a, C3, and E l can be isolated from the culture medium and separated from other substances which may be present by adsorptive and extractive techniques. Adsorptive techniques are preferred because such procedures avoid the use of large volumes of solvents required in extraction processes.
  • Since the procedures for exemplifying the present invention are substantially the same when using strains ATCC 31680 (for isolation of antibiotic A-4696 factors B2 and C3), ATCC 31682 (for isolation of antibiotic A-4696 factors B1 and C1a), and ATCC 31683 (for isolation of antibiotic A-4696 factors B3 and E1), the use of only ATCC 31682 is presented here for simplicity. Certain procedural differences relating to the production medium and the use of strain ATCC 31683 are also presented in Example 1 where appropriate. Accordingly this invention is exemplified by the following examples:
  • Example 1 A. Shake Flask Fermentation
  • Mycelial fragments of Actinoplanes missouriensis, illustrated here with strain ATCC 31682 for simplicity, were inoculated on a nutrient agar slant having the following composition:
    Figure imgb0036
  • The slant inoculated with ATCC 31682 was then incubated for 6 days at 30°C. The culture does not sporulate so it is necessary to macerate the mycelial mat with a sterile pipette. The macerated mature culture was covered with sterile distilled water and scraped carefully with the pipette or a sterile rod to obtain a mycelial suspension.
  • The suspension thus obtained was used to inoculate 100 ml. of a sterile vegetative medium having the following composition:
    Figure imgb0037
  • The inoculated vegetative medium was grown for 48 hours at 30°C. on a rotary shaker operating at 250 rpm. Ten ml. of the inoculated vegetative medium was inoculated into 100 ml. of a sterile "bump" medium of the following composition.
    Figure imgb0038
  • The inoculated "bump" medium was incubated for 24 hours at 30°C. with constant shaking on a rotary shaker operating at 250 rpm.
  • Four-tenths ml. of the "bump" medium was inoculated into 100 ml. portions of a production medium of the composition shown below contained in 500 ml. Erlenmeyer flasks, and sterilized at 121°C. for 30 minutes.
    Figure imgb0039
  • The production fermentation was shaken for about 96 hours at a temperature of 30°C. on a rotary shaker operating at 250 rpm. The pH at the end of the fermentation cycle was about 8.0.
  • For production of antibiotic A-4696 factors B3 and E1, strain ATCC 31683 was used to prepare the "bump" medium according to the teaching disclosed above. Four-tenths ml. of the strain ATCC 31683 "bump" medium was inoculated into 100 ml. portions of a production medium of the composition shown below contained in 500 ml. Erienmeyer flasks, and sterilized at 121°C. for 30 minutes.
    Figure imgb0040
  • The production fermentation was shaken for about 96 hours at a temperature of 30°C. on a rotary shaker operating at 250 rpm. The pH at the end of the fermentation cycle was about 8.0.
  • B. 40-liter tank fermentation
  • The preparation of the inoculum proceeded through the incubation of the "bump" medium detailed under section A, above. Twenty-five liters of a production medium as outlined above, was sterilized by autoclaving at 121°C. for 30 minutes and charged into a 40 1. capacity fermentation tank. One-hundred ml. of "bump" medium was inoculated into the sterile production medium. The inoculated production medium was allowed to ferment for 4 days at 30°C. The fermentation was aerated with sterile air in an amount of about one-half volume of air per volume of culture medium per minute. The fermenting production medium was agitated with a mixer utilizing an impeller to insure adequate mixing of air with the medium. The pH of the culture medium gradually increased from an initial level cf about 6.5 to about 8.0 as the fermentation proceeded.
  • C. Isolation of Antibiotic A-4696.
  • Fermentation broth (3800 1.) prepared according to the above procedure was filtered after the addition of 5% (wt/vol) filter aid (Celite 545). The filter cake was resuspended in deionized water (3600 1.) and the pH of the aqueous suspension was adjusted to pH 10.5 using aqueous sodium hydroxide. The suspended solids were separated by filtration and washed with water. The filtrate and the washings were combined and the resulting solution was acidified with 20% (wt/vol) aqueous sulfuric acid to pH 4.5. The acidic solution was clarified by filtration using 1% filter aid (Celite 545). The clear solution was passed through a column (1.8 x 5 ft.) containing 350 1. of Amberlite IR-116 (Na+ form) and the column was washed with deionized water (1200 1.). The IR-116 resin was removed from the column and eluted batchwise at pH 10.5 with an aqueous solution of sodium hydroxide (total 1000 liters). The resin eluate was neutralized (pH 7) with 20% (wt/vol) aqueous sulfuric acid, then washed with three portions of deionized water (150 liters total). The water washes were neutralized and combined with the neutralized eluate. The resulting solution was concentrated and subsequently freeze dried. The preparation of the crude complex varied in color from tan to dark brown.
  • D. Removal of Salts from Crude Antibiotic A-4696.
  • The crude complex (1.0 kg) was slowly added with vigorous stirring to deionized water (1.5 liters). The resulting suspension was stirred for twenty minutes and was subsequently neutralized (pH 7) using a 10% aqueous ammonium hydroxide solution. The insoluble antibiotic A-4696 complex was separated by vacuum filtration, washed with deionized water, and freeze dried. The dried, desalted, complex was recovered in approximately 80% yield (based on bioactivity).
  • E. Purification of Desalted Antibiotic A-4696.
  • The dried, desalted complex (300 g.) was suspended in deionized water (2 liters), and the pH of the suspension was adjusted to pH 2.7 by addition of 3N aqueous hydrochloric acid. The acidified solution was centrifuged for 40 minutes at 2500 rpm. The supernatant was decanted and loaded on a column (8 x 85 cm) containing 6 liters of decolorizing resin (Duolite S761). The activity was eluted with deionized water at a flow rate of 30 ml/min. The elution was monitored by thin layer chromatography. The antibiotic A-4696-containing effluent was concentrated (3 mm., 35°C.) to a volume of 3 liters and freeze dried. The decolorized complex was recovered as a white-to-tan solid in approximately 70% yield (based on bioactivity).
  • F. Isolation of Antibiotic A-4696 Factors B1, B2, B3, C1a, C3, and E1Hydrochloride Salts
  • The dried, decolorized antibiotic A-4696 complex (10 g.) was dissolved in 100 ml. of deionized water. The resulting aqueous solution was filtered and loaded on a chromatography column (5 x 100 cm.) containing 2 liters of polyamide (Machery & Nagel SC6). The column was eluted with deionized water and 200-300 fractions (25 ml. each) were collected. The elution was monitored by UV-activity and by thin layer chromatography. Fractions were combined according to TLC identity and freeze dried. For some of the separations it was necessary to double the column length (200 cm.) by using two of the polyamide columns in line. Additional purification was achieved by repeated chromatography.
  • The procedures outlined in A-F above are followed using strain ATCC 31682, when isolation of antibiotic A-4696 factors B1 and Cla is desired, using strain ATCC 31680 when isolation of A-4696 factors B2 and C3 is desired, and using strain ATCC 31683 when isolation of antibiotic A-4696 factors B3 and E1 is desired. While other Actinoplanes strains may be used for isolation of the above aforementioned factors, the strains disclosed are preferred for isolation of the antibiotic A-4696 factors claimed herein.
  • An alternative method for isolating antibiotic A-4696 factors B1, B2, B3' C1a, C3, and E 1 as hydrochloride salts using a single Actinoplanes missouriensis strain is as follows:
    • The dried, decolorized antibiotic A-4696 complex (200 mg. prepared from Strain 31683 according to the teaching of Example 1, A-E above) was dissolved in about 2 ml. distilled water. The resulting aqueous solution was filtered and separated by column chromatography using reversed phase adsorbents such as, for example, Li ChroprepR RP-18* as the stationary phase and aqueous acetonitrile gradients containing triethylamine phosphate as the mobile phase. Although it is understood that those skilled in the art will vary the acetonitrile concentration gradient depending upon the composition of a particular fermentation, a preferred concentration gradient is 10-40%. The column effluent was monitored by UV-activity and fractions containing the individual factors were collected. The acetonitrile was removed by evaporation under high vacuum and the resulting aqueous solutions were freeze dried. The freeze dried chromatography fractions were then redissolved in distilled water, adsorbed on reversed phase adsorbents such as, for example, Sep PakR C18 cartridges ** and eluted with 50% aqueous methanol. The aqueous solutions containing the individual antibiotic A-4696 factors were evaporated to dryness and the purified antibiotic A-4696 factors were then recovered as dry amorphous solids.
  • * Available from E. Merck, Darmstadt, Germany ** Available from Waters Associates Inc., Milford, Massachusetts
  • Example 2 Preparation of Antibiotic A-4696 factors B1, B2, B3' C1a, C 3, and E1 as Sulfate Salts
  • Antibiotic A-4696 (300 g. prepared according to the teaching of Example 1, A-D) was suspended in deionized water (2 liters), and the pH of the suspension was adjusted to pH 2.7 by addition of 3N aqueous sulfuric acid. The acidified solution was centrifuged for 40 minutes at 2500 rpm. The supernatant was decanted and loaded on a column (8 x 85 cm) containing 6 liters of decolorizing resin (Duolite S761). The activity was eluted with deionized water at a flow rate of 30 ml./min. The elution was monitored by thin layer chromatography. The antibiotic A-4696-containing effluent was concentrated (3 mm., 35°C.) to a volume of 3 liters and freeze dried. The decolorized complex was recovered as a white-to-tan solid in approximately 70% yield (based on bioactivity). The individual A-4696 factors B1, B2' B3, C1a, C3, and E1 sulfates were isolated according to the teaching of Example 1, F.

Claims (48)

1. An antibiotic A-4696 complex when produced by submerged aerobic cultivation of Actinoplanes missouriensis strain ATCC 31680, ATCC 31682 or ATCC 31683.
2. Antibiotic A-4696 factor B1, or a pharmaceutically acceptable acid addition salt thereof, which factor in the form of its hydrochloride salt is a white, crystalline substance soluble in water and hydroxylic and polar solvents, and insoluble in ether, chloroform, benzene, acetone, alipatic hydrocarbons, and chlorinated hydrocarbons; has the approximate composition of 51.51 percent carbon, 5.25 percent hydrogen, 4.88 percent nitrogen, 4.62 percent chlorine, and oxygen comprising the remainder; has an approximate theoretical molecular weight of 1954; has an ultraviolet absorption maximum in water at 280 nm with an
Figure imgb0041
of 42.8; and has the following distinguishable bands in its infrared absorption spectrum when determined in KBr: 3380 broad, 2930, 1731, 1693, 1654, 1637, 1615, 1588, 1577, 1521, 1503, 1488, 1423, 1321, 1289, 1229, 1210, 1178, 1154, 1121, 1076, 1060, 1030, 1012, 982, 880, 842, 831, and 810 cm-1.
3. Antibiotic A-4696 factor B2, or a pharmaceutically acceptable acid addition salt thereof, which factor in the form of its hydrochloride salt is a white, crystalline substance soluble in water and hydroxylic and polar solvents, and insoluble in ether, chloroform, benzene, acetone, aliphatic hydrocarbons, and chlorinated hydrocarbons; has the approximate composition of 51.96 percent carbon, 4.67 percent hydrogen, 5.72 percent nitrogen, 5.88 percent chlorine, and oxygen comprising the remainder; has an approximate theoretical molecular weight of 1808; has an ultraviolet absorption maximum in water at 280 nm with an
Figure imgb0042
of 44.7; and has the following distinguishable bands in its infrared absorption spectrum when determined in KBr; 3409 broad, 2934, 1730, 1658, 1614, 1588, 1548, 1504, 1498, 1490, 1426, 1290, 1231, 1210, 1179, 1121, 1061, 1031, 1017, 987, 903, 884, and 818 cm-1.
4. Antibiotic A-4696 factor B3, or a pharmaceutically acceptable acid addition salt thereof, which factor in the form of its hydrochloride salt is a white, crystalline substance soluble in water and hydroxylic and polar solvents, and insoluble in ether, chloroform, benzene, acetone, aliphatic hydrocarbons, and chlorinated hydrocarbons; has the approximate composition of 51.84 percent carbon, 4.74 percent hydrogen, 5.83 percent nitrogen, 5.57 percent chlorine, and oxygen comprising the remainder; has an approximate theoretical molecular weight of 1808; has an ultraviolet absorption maximum in water at 280 nm with an
Figure imgb0043
of 46.3; and has the following distinguishable bands in its infrared absorption spectrum when determined in KBr: 3394 broad, 2938, 1733, 1697, 1675, 1656, 1638, 1614, 1591, 1515, 1504, 1489, 1427, 1359, 1291, 1228, 1209, 1180, 1120, 1072, 1051, 1018, 985, 903, 882, 846, and 816 cm-1.
5. Antibiotic A-4696 factor C1a, or a pharmaceutically acceptable acid addition salt thereof, which factor in the form of its hydrochloride salt is a white, crystalline substance soluble in water and hydroxylic and polar solvents, and insoluble in ether, chloroform, benzene, acetone, aliphatic hydrocarbons, and chlorinated hydrocarbons; has the approximate composition of 53.05 percent carbon, 4.74 percent hydrogen, 5.83 percent nitrogen, 5.39 percent chlorine, and oxygen comprising the remainder; has an approximate theoretical molecular weight of 1792; has an ultraviolet absorption maximum in water at 279 nm with an
Figure imgb0044
of 47.9; and has the following distinguishable bands in its infrared absorption spectrum when determined in KBr; 3380 broad, 2931, 1734, 1650, 1616, 1591, 1505, 1491, 1427, 1359, 1290, 1228, 1213, 1177, 1123, 1072, 1061, 1032, 1017, 987, 903, 832, 814, and 715 cm
6. Antibiotic A-4696 factor C3, or a pharmaceutically acceptable acid addition salt thereof, which factor in the form of its hydrochloride salt is a white, crystalline substance soluble in water and hydroxylic and polar solvents, and insoluble in ether, chloroform, benzene, acetone, aliphatic hydrocarbons, and chlorinated hydrocarbons; has the approximate composition of 51.73 percent carbon, 4.69 percent hydrogen, 5.94 percent nitrogen, 6.02 percent chlorine, and oxygen comprising the remainder; has an ultraviolet absorption maximum in water at 280 nm with an
Figure imgb0045
of 47.9; and has the following distinguishable bands in its infrared absorption spectrum determined in KBr; 3378 broad, 2925, 1728, 1689, 1658, 1637, 1616, 1589, .l579, 1573, 1546, 1536, 1529, 1523, 1503, 1489, 1474, 1457, 1426, 1421, 1397, 1387, 1286, 1231, 12Q6, 1121, 1075, 1062, 1028, 1012, 987, 965, 949, 878, 840, 816, 769, 708 cm-1.
7. Antibiotic A-4696 factor E1, or a pharmaceutically acceptable acid addition salt thereof, which factor in the form of its hydrochloride salt is a white, crystalline substance soluble in water and hydroxylic and polar solvents, and insoluble in ether, chloroform, benzene, acetone, aliphatic hydrocarbons, and chlorinated hydrocarbons; has the approximate composition of 50.71 percent carbon, 4.70 percent hydrogen, 9.01 percent nitrogen, 1.84 percent chlorine, and oxygen comprising the remainder; has an ultraviolet absorption maximum in water at 279 nm with an
Figure imgb0046
of 39.9; and has the following distinguishable bands in its infrared absorption spectrum when determined in KBr: 3394 broad, 2933, 1657, 1636, 1610, 1589, 1538, 1511, 1505, 1453, 1424, 1393, 1369, 1328, 1320, 1291, 1232, 1212, 1178, 1120, 1075, 1061, 1031, 1018, 986, 973, 904, 878, 847, 813, 770, 752, 738, and 714 cm-1.
8. A process for the preparation of antibiotic A-4696 complex which comprises cultivating Actinoplanes missouriensis strain ATCC 31680, ATCC 31682 or ATCC 31683 in a culture medium containing assimilable sources of carbohydrate, nitrogen and inorganic salts under submerged aerobic fermentation conditions until a substantial amount of antibiotic activity is produced.
9. The process of claim 8 which includes the additional step of isolating the A-4696 complex from the culture medium.
10. The process of claim 9 wherein A-4696 factors B2 and C3 are isolated from the A-4696 complex produced by Actinoplanes missouriensis ATCC 31680.
11. The process of claim 9 wherein A-4696 factors B1 and C1a are isolated from the A-4696 complex produced by Actinoplanes missouriensis ATCC 31682.
12. The process of claim 9 wherein A-4696 factors B3 and E1 are isolated from the A-4696 complex produced by Actinoplanes missouriensis ATCC 31683.
13. The process of claim 9 wherein A-4696 factors B1, B2, B3, C1a, C3 and E1 are isolated from the A-4696 complex produced by Actinoplanes missouriensis ATCC 31683.
14. Actinoplanes missouriensis ATCC 31680.
15. A culture medium containing Actinoplanes missouriensis ATCC 31680 and assimiliable sources of carbon, nitrogen and inorganic salts.
16. Actinoplanes missouriensis ATCC 31682.
17. A culture medium containing Actinoplanes missouriensis ATCC 31682 and assimiliable sources of carbon, nitrogen and inorganic salts.
18. Actinoplanes missouriensis ATCC 31683.
19. A culture medium containing Actinoplanes missouriensis ATCC 31683 and assimiliable sources of carbon, nitrogen and inorganic salts.
20. A method for increasing the feed utilization efficiency in ruminant animals having a developed rumen which comprises orally administering to the ruminant animals a growth promotant amount of a compound, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 7.
21. A feed for ruminant animals which comprises as active ingredient a growth promotant amount of a compound, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 7.
22. A feed premix for ruminant animals which contains from about 1.0 percent to about 90.0 percent of a compound, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 7.
23. A feed supplement for ruminant animals which contains a compound, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 7 at a concentration by weight of about 0.01 percent to about 1.0 percent. `v
24. A method of promoting the growth of chickens which comprises administering to the chickens a growth promotant amount of a compound, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 7.
25. The method of claim 24 wherein a growth promotant amount of a compound, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 7 is incorporated in the chicken's diet.
26. The method of claim 24 wherein a growth promotant amount of a compound, or a pharmaceutically acceptable salt thereof, as claimed is any one of claims 1 to 7 is incorporated into the chicken's drinking water.
27. An A-4696 complex as described in claim 1 for use as an antibiotic.
28. An A-4696 complex as described in claim 1 for use as a growth promotant.
29. An A-4696 factor B1' B2' B3, C1a, C3 and/or E1 for use as an antibiotic.
30. An A-4696 factor B1, B2, B 3' C1a, C 3 and/or E1 for use as a growth promotant.
31. A method for promoting growth in an animal which comprises administering a compound according to any of claims 1 to 7 or a pharmaceutically- acceptable acid addition salt thereof.
1. A process for the preparation of antibiotic A-4696 complex which comprises cultivating Actinoplanes missouriensis strain ATCC 31680, ATCC 31682 or ATCC 31683 in a culture medium containing assimilable sources of carbohydrate, nitrogen and inorganic salts under submerged aerobic fermentation conditions until a substantial amount of antibiotic activity is produced.
2. The process of claim 1 which includes the additional step of isolating the A-4696 complex from the culture medium.
3. The process of claim 1 or 2 wherein antibiotic A-4696 factor Bl, or a pharmaceutically acceptable acid addition salt thereof, which factor in the form of its hydrochloride salt is a white, crystalline substance soluble in water and hydroxylic and polar solvents, and insoluble in ether, chloroform, benzene, acetone, alipatic hydrocarbons, and chlorinated hydrocarbons; has the approximate composition of 51.51 percent carbon, 5.25 percent hydrogen, 4.88 percent nitrogen, 4.62 percent chlorine, and oxygen comprising the remainder; has an approximate theoretical molecular weight of 1954; has an ultraviolet absorption maximum in water at 280 nm with an
Figure imgb0047
of 42.8; and has the following distinguishable bands in its infrared absorption spectrum when determined in KBr: 3380 broad, 2930, 1731, 1693, 1654, 1637, 1615, 1588, 1577, 1521, 1503, 1488, 1423, 1321, 1289, 1229, 1210, 1178, 1154, 1121, 1076, 1060, 1030, 1012, 982, 880, 842, 831, and 810 cm-1 is isolated from the A-4696 complex produced by Actinoplanes missouriensis ATCC 31682 or ATCC 31683.
4. The process of claim 1 or 2 wherein antibiotic A-4696 factor B2, or a pharmaceutically acceptable acid addition salt thereof, which factor in the form of its hydrochloride salt is a white, crystalline substance soluble in water and hydroxylic and polar solvents, and insoluble in ether, chloroform, benzene, acetone, aliphatic hydrocarbons, and chlorinated hydrocarbons; has the approximate composition of 51.96 percent carbon, 4.67 percent hydrogen, 5.72 percent nitrogen, 5.88 percent chlorine, and oxygen comprising the remainder; has an approximate theoretical molecular weight of 1808; has an ultraviolet absorption maximum in water at 280 nm with an
Figure imgb0048
of 44.7; and has the following distinguishable bands in its infrared absorption spectrum when determined in KBr; 3409 broad, 2934, 1730, 1658, 1614, 1588, 1548, 1504, 1498, 1490, 1426, 1290, 1231, 1210, 1179, 1121, 1061, 1031, 1017, 987, 903, 884, and 818 cm-1 is isolated from the A-4696 complex produced by Actinoplanes missouriensis ATCC 31680 or ATCC 31683.
5. The process of claim 1 or 2 wherein antibiotic A-4696 factor B3, or a pharmaceutically acceptable acid addition salt thereof, which factor in the form of its hydrochloride salt is a white, crystalline substance soluble in water and hydroxylic and polar solvents, and insoluble in ether, chloroform, benzene, acetone, aliphatic hydrocarbons, and chlorinated hydrocarbons; has the approximate composition of 51.84 percent carbon, 4.74 percent hydrogen, 5.83 percent nitrogen, 5.57 percent chlorine, and oxygen comprising the remainder; has an approximate theoretical molecular weight of 1808; has an ultraviolet absorption maximum in water at 280 nm with an
Figure imgb0049
of 46.3; and has the following distinguishable bands in its infrared absorption spectrum when determined in KBr: 3394 broad, 2938, 1733, 1697, 1675, 1656, 1638, 1614, 1591, 1515, 1504, 1489, 1427, 1359, 1291, 1228, 1209, 1180, 1120, 1072, 1051, 1018, 985, 903, 882, 846, and 816 cm 1 is isolated from the A-4696 complex produced by Actinoplanes missouriensis ATCC 31683.
6. The process of claim 1 or 2 wherein antibiotic A-4696 factor Cla, or a pharmaceutically acceptable acid addition salt thereof, which factor in the form of its hydrochloride salt is a white,.crystalline substance soluble in water and hydroxylic and polar solvents, and insoluble in ether, chloroform, benzene, acetone, aliphatic hydrocarbons, and chlorinated hydrocarbons; has the approximate composition of 53.05 percent carbon, 4.74 percent hydrogen, 5.83 percent nitrogen, 5.39 percent chlorine, and oxygen comprising the remainder; has an approximate theoretical molecular weight of 1792; has an ultraviolet absorption maximum in water at 279 nm with an
Figure imgb0050
of 47.9; and has the following distinguishable bands in its infrared absorption spectrum when determined in KBr; 3380 broad, 2931, 1734, 1650, 1616, 1591, 1505, 1491, 1427, 1359, 1290, 1228, 1213, 1177, 1123, 1072, 1061, 1032, 1017, 987, 903, 832, 814, and 715 cm-1 is isolated from the A-4696 complex produced by Actinoplanes missouriensis ATCC 31682 or ATCC 31683.
7. The process of claim 1 or 2 wherein antibiotic A-4696 factor C3, or a pharmaceutically acceptable acid addition salt thereof, which factor in the form of its hydrochloride salt is a white, crystalline substance soluble in water and hydroxylic and polar solvents, and insoluble in ether, chloroform, benzene, acetone, aliphatic hydrocarbons, and chlorinated hydrocarbons; has the approximate composition of 51.73 percent carbon, 4.69 percent hydrogen, 5.94 percent nitrogen, 6.02 percent chlorine, and oxygen comprising the remainder; has an ultraviolet absorption maximum in water at 280 nm with an
Figure imgb0051
of 47.9; and has the following distinguishable bands in its infrared absorption spectrum determined in KBr; 3378 broad, 2925, 1728, 1689, 1658, 1637, 1616, 1589, 1579, 1573, 1546, 1536, 1529, 1523, 1503, 1489, 1474, 1457, 1426, 1421, 1397, 1387, 1286, 1231, 1206, 1121, 1075, 1062, 1028, 1012, 987, 965, 949, 878, 840, 816, 769, 708 cm-1 is isolated from the A-4696 complex produced by Actinoplanes missouriensis ATCC 31680 or ATCC 31683.
8. The process of claim 1 or 2 wherein antibiotic A-4696 factor E1, or a pharmaceutically acceptable acid addition salt thereof, which factor in the form of its hydrochloride salt is a white, crystalline substance soluble in water and hydroxylic and polar solvents, and insoluble in ether, chloroform, benzene, acetone, aliphatic hydrocarbons, and chlorinated hydrocarbons; has the approximate composition of 50.71 percent carbon, 4.70 percent hydrogen, 9.01 percent nitrogen, 1.84 percent chlorine, and oxygen comprising the remainder; has an ultraviolet absorption maximum in water at 279 nm with an
Figure imgb0052
of 39.9; and has the following distinguishable bands in its infrared absorp-. tion spectrum when determined in KBr: 3394 broad, 2933, 1657, 1636, 1610, 1589, 1538, 1511, 1505, 1453, 1424, 1393, 1369, 1328, 1320, 1291, 1232, 1212, 1178, 1120, 1075, 1061, 1031, 1018, 986, 973, 904, 878, 847, 813, 770, 752, 738, and 714 cm-1 is isolated from the A-4696 complex produced by Actinoplanes missouriensis ATCC 31683.
9. Actinoplanes missouriensis ATCC 31680.
10. A culture medium containing Actinoplanes missouriensis ATCC 31680 and assimiliable sources of carbon, nitrogen and inorganic salts.
11. Actinoplanes missouriensis ATCC 31682.
12. A culture medium containing Actinoplanes missouriensis ATCC 31682 and assimiliable sources of carbon, nitrogen and inorganic salts.
13. Actinoplanes missouriensis ATCC 31683.
14. A culture medium containing Actinoplanes missouriensis ATCC 31683 and assimiliable sources of carbon, nitrogen and inorganic salts.
15. A method for increasing the feed utilization efficiency in ruminant animals having a developed rumen which comprises orally administering to the ruminant animals a growth promotant amount of a compound, or a pharmaceutically acceptable salt thereof, prepared according to any one of claims 1 to 8.
16. A feed for ruminant animals which comprises as active ingredient a growth promotant amount of a compound, or a pharmaceutically acceptable salt thereof, prepared according to any one of claims 1 to 8.
17. A method of promoting the growth of chickens which comprises administering to the chickens a growth promotant amount of a compound, or a pharmaceutically acceptable salt thereof, prepared according to any one of claims 1 to 8.
EP81305898A 1980-12-18 1981-12-16 Antibiotic a-4696 factors b1,b2,b3,c1a,c3 and e1 Expired EP0055070B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT81305898T ATE23192T1 (en) 1980-12-18 1981-12-16 ANTIBIOTIC A-4696, FACTORS B1, B2, B3, C1A, C3 AND E1.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/217,962 US4322406A (en) 1980-12-18 1980-12-18 Antibiotic A-4696 factors B1, B2, B3, C1a, C3 and E1
US217962 1980-12-18

Publications (2)

Publication Number Publication Date
EP0055070A1 true EP0055070A1 (en) 1982-06-30
EP0055070B1 EP0055070B1 (en) 1986-10-29

Family

ID=22813191

Family Applications (1)

Application Number Title Priority Date Filing Date
EP81305898A Expired EP0055070B1 (en) 1980-12-18 1981-12-16 Antibiotic a-4696 factors b1,b2,b3,c1a,c3 and e1

Country Status (26)

Country Link
US (1) US4322406A (en)
EP (1) EP0055070B1 (en)
JP (1) JPS57132888A (en)
KR (1) KR850001503B1 (en)
AR (1) AR228377A1 (en)
AT (1) ATE23192T1 (en)
AU (1) AU547906B2 (en)
CA (1) CA1171008A (en)
CS (1) CS228909B2 (en)
DD (2) DD202048A5 (en)
DE (1) DE3175527D1 (en)
DK (1) DK562281A (en)
ES (1) ES508085A0 (en)
FI (1) FI813958L (en)
GB (1) GB2089814B (en)
GR (1) GR77286B (en)
HU (1) HU189548B (en)
IE (1) IE51883B1 (en)
IL (1) IL64485A (en)
NZ (1) NZ199197A (en)
PH (1) PH18801A (en)
PL (1) PL134197B1 (en)
PT (1) PT74137B (en)
RO (1) RO82520A (en)
YU (1) YU292881A (en)
ZA (1) ZA818632B (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0090578A2 (en) * 1982-03-24 1983-10-05 Eli Lilly And Company A41030 antibiotics and their production
EP0095295A1 (en) * 1982-05-21 1983-11-30 Eli Lilly And Company Cyclic peptide derivatives
EP0100605A1 (en) * 1982-07-30 1984-02-15 Eli Lilly And Company A47934 antibiotic and its production
EP0112184A2 (en) * 1982-12-20 1984-06-27 Eli Lilly And Company Antibiotic A51568 factors A and B
GB2138822A (en) * 1983-04-27 1984-10-31 Lilly Co Eli Actaplanin antibiotics
EP0142285A2 (en) * 1983-10-21 1985-05-22 Eli Lilly And Company Glycopeptide bioconversion products
EP0142940A2 (en) * 1983-10-21 1985-05-29 Eli Lilly And Company N-acyl glycopeptide derivatives
EP0145180A2 (en) * 1983-10-21 1985-06-19 Eli Lilly And Company Novel glycopeptide derivatives
EP0150565A1 (en) * 1983-10-21 1985-08-07 Eli Lilly And Company Glycopeptide antibiotic cuc/csv and processes for its production
EP0159436A2 (en) * 1983-10-21 1985-10-30 Eli Lilly And Company Novel bioconverting microorganisms
EP0177771A2 (en) * 1984-10-11 1986-04-16 The Dow Chemical Company Antibiotic A26201-1 and antibiotic A26201-2 produced by a novel strain of Actinoplanes
EP0241758A2 (en) * 1986-04-11 1987-10-21 GRUPPO LEPETIT S.p.A. A process for recovery of glycopeptidic antibiotics

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537770A (en) * 1982-03-24 1985-08-27 Eli Lilly And Company A41030 antibiotics
US4713331A (en) * 1982-03-24 1987-12-15 Eli Lilly And Company Microbial production of A41030 antibiotics
US4604239A (en) * 1982-03-24 1986-08-05 Eli Lilly And Company Antibiotics
US4559323A (en) * 1982-03-24 1985-12-17 Eli Lilly And Company A41030 Antibiotics
US4524135A (en) * 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
US4558009A (en) * 1982-12-20 1985-12-10 Eli Lilly And Company Process for producing antibiotic A-51568 by fermentation and microorganism
US4548974A (en) * 1983-07-13 1985-10-22 Smithkline Beckman Corporation Antibiotics produced by Kibdelosporangium aridum shearer
US4672036A (en) * 1983-07-13 1987-06-09 Smithkline Beckman Corporation Pure cultures of Kibdelsporangium aridum Shearer gen. nov., sp. nov. ATCC 39323 and mutants thereof
US4663282A (en) * 1983-10-21 1987-05-05 Eli Lilly And Company Glycopeptide antibiotic CUC/CSV and process for its production
US4558008A (en) * 1983-12-13 1985-12-10 Eli Lilly And Company Process for production of A-51568B antibiotic
AU579120B2 (en) * 1983-12-16 1988-11-17 Gruppo Lepetit S.P.A. Chemical process for preparing antibiotic L 17392 (deglucoteicoplanin) and its salts
US4558036A (en) * 1984-02-17 1985-12-10 Eli Lilly And Company Actaplanin antibiotics
US4859599A (en) * 1984-10-11 1989-08-22 The Dow Chemical Company Antibiotic A26201-1 and antibiotic A26201-2 produced by a novel strain of actinoplanes
GB8624251D0 (en) * 1986-10-09 1986-11-12 Erba Farmitalia "1,2-beta-methylene-4-substituted androstene-3,17 dione derivatives
US4939244A (en) * 1987-01-30 1990-07-03 American Cyanamid Company Pseudoaglycones of LL-E33288 antibiotics
US4845194A (en) * 1987-02-27 1989-07-04 Eli Lilly And Company Glycopeptide recovery process
US5213797A (en) * 1987-07-13 1993-05-25 Eli Lilly And Company A80407 antibiotics
US4996148A (en) * 1987-07-13 1991-02-26 Eli Lilly And Company A80407 antibiotics

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952095A (en) * 1972-06-02 1976-04-20 Eli Lilly And Company Novel antibiotic and a process for the production thereof
US4064233A (en) * 1974-12-17 1977-12-20 Eli Lilly And Company Antibiotic A-4696
US4115552A (en) * 1976-04-19 1978-09-19 Eli Lilly And Company Factor A and B of antibiotic A-4696
GB2045231A (en) * 1979-04-07 1980-10-29 Lepetit Spa Antibiotic A/16686 and its preparation from actinoplanes
GB1578480A (en) * 1977-05-19 1980-11-05 Lilly Co Eli Antibiotic a-35512 and process for production thereof
EP0031221A1 (en) * 1979-12-13 1981-07-01 Eli Lilly And Company Cyclic peptide nuclei

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952095A (en) * 1972-06-02 1976-04-20 Eli Lilly And Company Novel antibiotic and a process for the production thereof
US4064233A (en) * 1974-12-17 1977-12-20 Eli Lilly And Company Antibiotic A-4696
US4115552A (en) * 1976-04-19 1978-09-19 Eli Lilly And Company Factor A and B of antibiotic A-4696
GB1578480A (en) * 1977-05-19 1980-11-05 Lilly Co Eli Antibiotic a-35512 and process for production thereof
GB2045231A (en) * 1979-04-07 1980-10-29 Lepetit Spa Antibiotic A/16686 and its preparation from actinoplanes
EP0031221A1 (en) * 1979-12-13 1981-07-01 Eli Lilly And Company Cyclic peptide nuclei

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0090578A3 (en) * 1982-03-24 1985-05-22 Eli Lilly And Company A41030 antibiotics and their production
EP0090578A2 (en) * 1982-03-24 1983-10-05 Eli Lilly And Company A41030 antibiotics and their production
EP0095295A1 (en) * 1982-05-21 1983-11-30 Eli Lilly And Company Cyclic peptide derivatives
EP0100605A1 (en) * 1982-07-30 1984-02-15 Eli Lilly And Company A47934 antibiotic and its production
EP0112184A2 (en) * 1982-12-20 1984-06-27 Eli Lilly And Company Antibiotic A51568 factors A and B
EP0112184A3 (en) * 1982-12-20 1985-06-19 Eli Lilly And Company Antibiotic a51568 factors a and b
EP0124343A1 (en) * 1983-04-27 1984-11-07 Eli Lilly And Company Actaplanin antibiotics
GB2138822A (en) * 1983-04-27 1984-10-31 Lilly Co Eli Actaplanin antibiotics
EP0145180A3 (en) * 1983-10-21 1985-07-10 Eli Lilly And Company Novel glycopeptide derivatives
EP0145180A2 (en) * 1983-10-21 1985-06-19 Eli Lilly And Company Novel glycopeptide derivatives
EP0142940A2 (en) * 1983-10-21 1985-05-29 Eli Lilly And Company N-acyl glycopeptide derivatives
EP0142285A3 (en) * 1983-10-21 1985-07-10 Eli Lilly And Company Glycopeptide bioconversion products
EP0142940A3 (en) * 1983-10-21 1985-07-10 Eli Lilly And Company N-acyl glycopeptide derivatives
EP0142285A2 (en) * 1983-10-21 1985-05-22 Eli Lilly And Company Glycopeptide bioconversion products
EP0150565A1 (en) * 1983-10-21 1985-08-07 Eli Lilly And Company Glycopeptide antibiotic cuc/csv and processes for its production
EP0159436A2 (en) * 1983-10-21 1985-10-30 Eli Lilly And Company Novel bioconverting microorganisms
EP0159436A3 (en) * 1983-10-21 1987-05-20 Eli Lilly And Company Novel bioconverting microorganisms
EP0177771A2 (en) * 1984-10-11 1986-04-16 The Dow Chemical Company Antibiotic A26201-1 and antibiotic A26201-2 produced by a novel strain of Actinoplanes
EP0177771A3 (en) * 1984-10-11 1988-03-09 The Dow Chemical Company Antibiotic a26201-1 and antibiotic a26201-2 produced by a novel strain of actinoplanes
EP0241758A2 (en) * 1986-04-11 1987-10-21 GRUPPO LEPETIT S.p.A. A process for recovery of glycopeptidic antibiotics
EP0241758A3 (en) * 1986-04-11 1989-09-27 Gruppo Lepetit S.P.A. A process for recovery of glycopeptidic antibiotics

Also Published As

Publication number Publication date
ATE23192T1 (en) 1986-11-15
YU292881A (en) 1983-10-31
DD204389A5 (en) 1983-11-30
FI813958L (en) 1982-06-19
RO82520A (en) 1983-09-26
IE51883B1 (en) 1987-04-15
AU547906B2 (en) 1985-11-14
ES8304203A1 (en) 1983-02-16
AR228377A1 (en) 1983-02-28
IE812971L (en) 1982-06-18
PT74137A (en) 1982-01-01
KR850001503B1 (en) 1985-10-11
AU7859881A (en) 1982-06-24
PL134197B1 (en) 1985-07-31
KR830007832A (en) 1983-11-07
PL234311A1 (en) 1982-08-16
ZA818632B (en) 1982-10-27
DE3175527D1 (en) 1986-12-04
NZ199197A (en) 1984-11-09
JPS57132888A (en) 1982-08-17
HU189548B (en) 1986-07-28
US4322406A (en) 1982-03-30
RO82520B (en) 1983-08-30
EP0055070B1 (en) 1986-10-29
DK562281A (en) 1982-06-19
GB2089814B (en) 1984-05-16
DD202048A5 (en) 1983-08-24
IL64485A0 (en) 1982-03-31
PH18801A (en) 1985-09-27
GB2089814A (en) 1982-06-30
IL64485A (en) 1985-01-31
PT74137B (en) 1984-05-09
ES508085A0 (en) 1983-02-16
CA1171008A (en) 1984-07-17
CS228909B2 (en) 1984-05-14
GR77286B (en) 1984-09-11

Similar Documents

Publication Publication Date Title
EP0055070B1 (en) Antibiotic a-4696 factors b1,b2,b3,c1a,c3 and e1
EP0055069B1 (en) Derivatives of actaplanin
US4115552A (en) Factor A and B of antibiotic A-4696
US3952095A (en) Novel antibiotic and a process for the production thereof
US4064233A (en) Antibiotic A-4696
US4375513A (en) Biologically pure culture of Actinoplanes missouriensis
US4918054A (en) Antibiotics called `chloropolysporins B and C`, a process for their preparation, and their therapeutic and veterinary use
US4548974A (en) Antibiotics produced by Kibdelosporangium aridum shearer
KR960012063B1 (en) Glycopeptide antibiotics pa-45052 and the preparation method thereof
US4174390A (en) Antibiotic A-7413 and process for preparation thereof
US4906618A (en) Prophylactic and therapeutic agent against swine dysentery
CA1088441A (en) Antibiotics, neoviridogriseins, and their method of production
EP0055071B1 (en) Antibiotic a-4696 factor g
US4672036A (en) Pure cultures of Kibdelsporangium aridum Shearer gen. nov., sp. nov. ATCC 39323 and mutants thereof
EP0211490B1 (en) Antibiotics of the vancomycin-class
US4463092A (en) Process for production antibiotic A53868
CA1090728A (en) Antibiotic a-7413 mixture comprising factors a,b,c and d and a process for producing it
EP0150565A1 (en) Glycopeptide antibiotic cuc/csv and processes for its production
US4797280A (en) Antibiotics produced by Kibdelosporangium aridum Shearer gen. nov., sp. nov. ATCC 39323
US4366147A (en) Antibiotic A-7413 and process for preparation thereof
JPH01240196A (en) Novel glycopeptide-based antibiotic pa-45052
DD210307A5 (en) PROCESS FOR PREPARING THE ANTIBIOTIC A53868 FACTOR A AND DERIVATIVES HEREVON
CS228936B2 (en) Preliminary fodder,or supplementary composition for preparing fodder for live stock,especially ruminants
HU190340B (en) Process for producing pseudoaglycon derivative of actaplanin
HU190430B (en) Process for producing inlusion complexes of beta-cyclodextrine and 17 hydroxy-7-alpha-mercapto-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid-gamma-lacton

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19811229

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LU NL SE

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 23192

Country of ref document: AT

Date of ref document: 19861115

Kind code of ref document: T

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19861201

Year of fee payment: 6

REF Corresponds to:

Ref document number: 3175527

Country of ref document: DE

Date of ref document: 19861204

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19861231

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19861231

Year of fee payment: 6

ITF It: translation for a ep patent filed

Owner name: MODIANO & ASSOCIATI S.R.L.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19870312

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Effective date: 19871216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19871217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19871231

Ref country code: CH

Effective date: 19871231

Ref country code: BE

Effective date: 19871231

BERE Be: lapsed

Owner name: ELI LILLY AND CY

Effective date: 19871231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19880701

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
GBPC Gb: european patent ceased through non-payment of renewal fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19880831

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19881121

EUG Se: european patent has lapsed

Ref document number: 81305898.9

Effective date: 19880913